Evaluating melanoma drug response and therapeutic escape with quantitative proteomics (Q33850665)

29 July 2017

Evaluating melanoma drug response and therapeutic escape with quantitative proteomics (English)

1 reference

29 July 2017

12

Keiran S M Smalley

1 reference

29 July 2017

10

Vernon K Sondak

1 reference

29 July 2017

4

Kim H T Paraiso

1 reference

29 July 2017

11

John M Koomen

1 reference

29 July 2017

3

Inna V Fedorenko

1 reference

29 July 2017

9

Geoffrey T Gibney

1 reference

29 July 2017

1

Vito W Rebecca

1 reference

29 July 2017

5

H Eirik Haarberg

1 reference

29 July 2017

8

Amod Sarnaik

1 reference

29 July 2017

Elizabeth Wood

2

1 reference

PubMed ID

24760959

29 July 2017

Yi Chen

series ordinal

6

1 reference

PubMed ID

24760959

29 July 2017

Yun Xiang

series ordinal

7

1 reference

29 July 2017

23 April 2014

1 reference

Molecular & Cellular Proteomics

29 July 2017

1 reference

29 July 2017

13

1 reference

29 July 2017

7

1 reference

29 July 2017

1844-1854

1 reference

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

The HSP70 family and cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

A modified HSP70 inhibitor shows broad activity as an anticancer agent

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Molecular pathways: targeting hsp90--who benefits and who does not.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Phosphoproteomic screen identifies potential therapeutic targets in melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Targeting the dynamic HSP90 complex in cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

HSP90 at the hub of protein homeostasis: emerging mechanistic insights

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Skyline: an open source document editor for creating and analyzing targeted proteomics experiments

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

A small molecule inhibitor of inducible heat shock protein 70.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

28 July 2018

Targeted cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4083119

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

28 July 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Absolute quantification of proteins in solutions and in polyacrylamide gels by mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Platform for Establishing Interlaboratory Reproducibility of Selected Reaction Monitoring-Based Mass Spectrometry Peptide Assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FMCP.M113.037424

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24760959

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1074/MCP.M113.037424

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

PubMed ID

24760959